<DOC>
	<DOC>NCT02753088</DOC>
	<brief_summary>The objective of the clinical study of the medicinal product for medical use: to compare efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with relapsing-remitting multiple sclerosis. Period of the clinical study of the medicinal product for medical use: from June 10, 2013 to March 23, 2016. Number of patients, involved into the study of the medicinal product for medical use: 158 patients.</brief_summary>
	<brief_title>Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Previously diagnosed multiple sclerosis (MS, McDonald criteria 2005); Disease more, than 1 year prior to inclusion; Presence of 1 relapse previously OR at least 1 Gd+ lesion in T1 regimen; EDSS 05,5; Absence of exacerbations for 4 weeks prior to inclusion; Readiness of patients (both genders) to use reliable methods of contraception (at least 1 barrier method in combination with: spermicides, intrauterine device/oral contraceptives) Secondary progressive and primary progressive forms of multiple sclerosis; Other diseases (except multiple sclerosis), which may affect the assessment of the severity of the symptoms of the underlying disease: mask, amplify, modify the symptoms of the underlying disease or cause the clinical manifestations and changes in the data of laboratory and instrumental methods of investigation similar to those of multiple sclerosis; Any acute or chronic infection in the acute stage; Verified HIV, hepatitis B and C, syphilis; Metabolic abnormalities (disorders), which manifest themselves as: 1. raising the general level of creatinine is more than 2 times over the upper limit of the normal range; 2. increase in transaminases (ALT, AST) or gammaglutamyltransferase more than 2.5 times over the upper limit of the normal range; Violation of bone marrow function as reducing the total number of leukocytes &lt;3000 /mcl, or a platelet count &lt;125000 /mcl, hemoglobin concentration reduction, or &lt;100 g / l; EDSS&gt; 5,5 points; Liver disease in the stage of decompensation; Congestive heart failure, or not controlled by a drug therapy angina or arrhythmia; Pregnancy, breastfeeding or planned pregnancy during the study period; Use of any time prior to study any drug for modifying multiple sclerosis: interferon beta1a, interferon beta1b, glatiramer acetate, azathioprine, corticosteroids and immunomodulators (except for treating exacerbations corticosteroids), drugs and monoclonal antibodies, cytotoxic and / or immunosuppressive drugs, including, but not limited to drugs: mitoxantrone, cyclophosphamide, cyclosporine, fingolimod, cladribine; or total lymphoid irradiation system; System (IV, oral) corticosteroids within 30 days prior to the screening visit; Intolerance or allergy to glatiramer acetate, mannitol or other components of the BCD063 preparations or Copaxone®Teva; History of drug addiction, alcoholism and abuse of drugs; Contraindications to MRI (gadolinium allergic to or intolerant of closed spaces, any renal failure, which may interfere with the removal of gadolinium an acute or chronic renal failure); Any malignancies, including in anamnesis; Vaccination within 4 weeks prior to study entry (prior to randomization); Participation in any other clinical trial within 30 days prior to screening or simultaneous participation in other clinical trials; Previous participation in this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Equivalence</keyword>
	<keyword>BCD-063</keyword>
	<keyword>Copaxone-Teva</keyword>
</DOC>